Contact our team if you would like additional educational information about compounded peptide formulations or pharmacy services
moles or raised lesions
Reported side effects are typically mild: Morning grogginess: Uncommon, usually associated with initial dosing or timing adjustments Vivid dreams: Some patients report more vivid dreams, which may reflect enhanced REM sleep Headache: Occasionally reported, usually mild and transient Injection site reactions: Minor redness or discomfort at the injection site DSIP has not demonstrated significant interactions with common medications in published studies
Our skilled podiatrist at Central Kansas Podiatry Associates, Dr
DISSECTION P938 - ESOC25-2421 CADASIL Argentine Registry (CADASILar): Establishing a Harmonized Clinical Protocol preliminary data Julieta Rosales 1 , Carolina Ardohain 2 , Juan Lopez 3 , Fabio Gonzalez 4 , Julian Alonso 5 , Valentin Selvaggi 6 , Diana Cristalli 7 , Ismael Calandri 2 1 Clinica Sagrada Familia-ENERI, Buenos Aires, Argentina, 2 FLENI, Buenos Aires, Argentina, 3 Sanatorio Los Arcos, Buenos Aires, Argentina, 4 Hospital Italiano de Bs As, Buenos Aires, Argentina, 5 Hospital Posadas, Buenos Aires, Argentina, 6 Hospital Ramos Meja, Buenos Aires, Argentina, 7 Centro Jesi, Buenos Aires, Argentina Background and Aims: CADASIL, a leading monogenic small vessel disease caused by NOTCH3 mutations, manifests with migraines, strokes, and cognitive decline
5.6 Neuroprotection Neuroinflammation induced by prolonged stimulation of glial cells and microglia is linked to neurodegenerative disorders
